This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Olympus Biotech International Ltd And BonAlive Biomaterials Ltd Announce Distribution Agreement

TURKU, Finland and LIMERICK, Ireland, January 21, 2013 /PRNewswire/ --

BonAlive Biomaterials Ltd, a manufacturer of implantable medical devices and an emerging leader in indications involving the treatment of chronically infected bone, and Olympus Biotech International Ltd, a wholly owned company of Olympus Corporation focused on minimally-invasive regenerative therapies in bone and soft tissues, today announced the signing of a multi-year exclusive distribution agreement. Under the agreement, Olympus Biotech International will have exclusive distribution rights for the BonAlive ®   granules product line in Germany, France and the UK. The product line covers regenerative products for orthopaedic and trauma  surgeries.

     (Logo: http://photos.prnewswire.com/prnh/20130121/589026-a )

     (Logo: http://photos.prnewswire.com/prnh/20130121/589026-b )

The agreement is an important milestone in the commercialization strategy of the BonAlive ® granules product line in the pathway of further expanding the access to hospitals in the large European markets.

"This newly established partnership enables us to work together with one of the most prominent leaders in the field of regenerative medicine in providing a complete portfolio of bone regeneration products to the community of orthopaedic and trauma surgeons" said Dr. Fredrik Ollila, CEO of BonAlive Biomaterials Ltd. "The establishment of a complete product offering will generate value and bring new opportunities in treatment of chronically infected bone".

"The cooperation and agreement with BonAlive Biomaterials Ltd completes our bone regeneration portfolio now also in the treatment of fractures and non-unions in patients with chronic infections. During our thorough global assessment of different technologies and options we were impressed by the clinical evidence and clinical data available for BonAlive®. We are very much convinced to have decided for a partnership with the company having the right approach to improve patient outcome" said Florian Kemmerich, President of Olympus Biotech International.

For more information about BonAlive Biomaterials Ltd, please visit http://www.bonalive.com

For more information about Olympus Biotech, visit http://www.olympusbiotech.com

About BonAlive Biomaterials Ltd

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,247.72 +189.37 1.18%
S&P 500 1,932.32 +18.47 0.97%
NASDAQ 4,691.4360 +55.3310 1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs